Tolerability and Activity of Ublituximab, Umbralisib, and Ibrutinib in Patients with Chronic Lymphocytic Leukaemia and Non-Hodgkin Lymphoma: A Phase 1 Dose Escalation and Expansion Trial

Drug Category: Array
Conference Category: Array
Lead Author: Nastoupil L, et al.
Published Date: 01/02/2019
Download Link: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(18)30216-3/fulltext
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top